Last 1,542 GBp
Change Today -12.50 / -0.80%
Volume 8.7M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
Frankfurt
As of 11:35 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Marc Dunover

Former Global Head of Rare Diseases and Chairman of GSK Japan, GlaxoSmithKline plc
AgeTotal Calculated CompensationThis person is connected to 21 board members in 2 different organizations across 4 different industries.

See Board Relationships
62296,000 GBP

Background*

Mr. Marc Dunover has been the Chief Financial Officer of AstraZeneca PLC since November 1, 2013. Mr. Dunover served as Executive Vice President of Global Portfolio & Product Strategy at AstraZeneca PLC from June 2013 to October 2013. He served as the Global Head of Rare Diseases Unit of JCR Pharmaceuticals Co., Ltd. He served as Head of Rare Diseases Unit at GlaxoSmithKline since February 2010. He served as President of Asia Pacific/Japan at GlaxoSmithKline plc until ...

Read Full Background

Corporate Headquarters*

980 Great West Road
Brentford, Middlesex TW8 9GS

United Kingdom

Phone: 44 20 8047 5000
Fax: --

Board Members Memberships*

Chairman
2010-N/A
Former Global Head of Rare Diseases Unit and Executive Director
2013-Present
Chief Financial Officer and Executive Director

Education*

MBA
Ecole des Hautes Etudes Commerciales de Montreal
LLB
Université de la Sorbonne - Université de Paris

Other Affiliations*

Annual Compensation*

Salary113,000 GBP
Bonus146,000 GBP
Total Annual Compensation259,000 GBP

Stock Options*

All Other Compensation37,000 GBP

Total Compensation*

Total Annual Cash Compensation296,000 GBP
Total Short Term Compensation259,000 GBP
Other Long Term Compensation37,000 GBP
Total Calculated Compensation296,000 GBP
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:LN 1,541.50 GBp -12.50

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
George A. Scangos Ph.D.Chief Executive Officer and Director
Biogen Idec Inc.
$1.5M
Brenton L. Saunders J.D.Chief Executive Officer, President and Director
Actavis plc
--
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
$1.3M
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
$1.5M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.